These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients. Luan FL; Kommareddi M; Ojo AO Transplantation; 2011 Jan; 91(2):237-44. PubMed ID: 21169881 [TBL] [Abstract][Full Text] [Related]
24. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. Boivin G; Gilbert C; Gaudreau A; Greenfield I; Sudlow R; Roberts NA J Infect Dis; 2001 Dec; 184(12):1598-602. PubMed ID: 11740736 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients. Díaz-Pedroche C; Lumbreras C; Del Valle P; San Juan R; Hernando S; Folgueira D; Andrés A; Delgado J; Meneu JC; Morales JM; Moreno E; Aguado JM Transplant Proc; 2005 Nov; 37(9):3766-7. PubMed ID: 16386532 [TBL] [Abstract][Full Text] [Related]
26. Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS. Kempen JH; Frick KD; Jabs DA Pharmacoeconomics; 2001; 19(12):1199-208. PubMed ID: 11772155 [TBL] [Abstract][Full Text] [Related]
27. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients. Grzywacz M; Deayton JR; Bowen EF; Wilson P; Emery VC; Johnson MA; Griffiths PD J Med Virol; 1999 Nov; 59(3):323-8. PubMed ID: 10502264 [TBL] [Abstract][Full Text] [Related]
28. Increased incidence of herpes zoster in the setting of cytomegalovirus preemptive therapy after kidney transplantation. Ko GB; Kim T; Kim SH; Choi SH; Kim YS; Woo JH; Kim YH; Park JB; Lee SK; Park SK; Park JS; Han DJ; Lee SO Transpl Infect Dis; 2013 Aug; 15(4):416-23. PubMed ID: 23676124 [TBL] [Abstract][Full Text] [Related]
29. Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation. Aigner C; Jaksch P; Winkler G; Czebe K; Taghavi S; Marta G; Klepetko W Wien Klin Wochenschr; 2005 Jul; 117(13-14):480-4. PubMed ID: 16091875 [TBL] [Abstract][Full Text] [Related]
30. The use of consensus guidelines for management of cytomegalovirus infection in renal transplantation. Dmitrienko S; Yu A; Balshaw R; Shapiro RJ; Keown PA; Kidney Int; 2007 Oct; 72(8):1014-22. PubMed ID: 17700642 [TBL] [Abstract][Full Text] [Related]
31. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Boivin G; Goyette N; Gilbert C; Humar A; Covington E Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409 [TBL] [Abstract][Full Text] [Related]
32. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Keven K; Basu A; Tan HP; Thai N; Khan A; Marcos A; Starzl TE; Shapiro R Transplant Proc; 2004 Dec; 36(10):3107-12. PubMed ID: 15686707 [TBL] [Abstract][Full Text] [Related]